Clinical Study on the Effect of Virechana in Sthaulya Vis-Vas obesity.

Randomized Clinical Comparative Study on the Effect of Virechana Followed with and without Dashanga Guggul in Sthaulya

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/06/014348

Enrollment

Registered

2018-06-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- With controlled Systemic disorders

Interventions

Intervention1: virechan without Dashang Guggul in Group B Rukshana Pachana Kvath:40ml/BD Triphala, Musta, Vidanga, Guduchi Choorna Ichabhedi Ras: 250mg Parada III Shunthi V Marich Gandhaka IV Tankana

Eligibility

Inclusion criteria

Inclusion criteria: 1.patients of clinical features of Sthaulya. 2.body mass index from 25kg/m2 to 35kg/m2. 3.patients of Sthaulya with controled HTN and DM. 4.Patients with total cholesterol less than 300mg/dl

Exclusion criteria

Exclusion criteria: 1.Patients of obesity due to hypothyroidism Cushingâ??s syndrome, Steroid induced obesity or Obesity due to any other systemic disorders. 2.Drug induced obesity for example Hormonal replacement therapy, calcium channel blockers, consumption of anabolic steroids etc. 3.Pregnant females & lactating mothers. 4.Patients who are currently participating in other clinical trials (since last six months). 5.Obesity because of heredity will be excluded.

Design outcomes

Primary

Measure	Time frame
1)To evaluate the effect of Snehpana on body mass index, waist hip ratio and lipid profile. 2)To evaluate the effect of Snehpana and Virechana separately on body mass index, waist hip ratio and lipid profile. 3)To evaluate the effect of Snehpana followed by Virechana and Dashang Guggul as Shamana drug on body mass index, waist hip ratio and lipid profile. Timepoint: 1)On zero day i.e. B.T.value 2)Rukshana Pachana Kvath will be given for 5 days. 3)From 6th day Snehapana will be administered for seven days and assessment will be done on 13th day. 4)Virechana will be given on 16 th day and assessment will be done on 21 rst day. 5) Final assessment will be done on 51 rst day i.e. Dashanga Guggulu will be given for 30 days.	—

Measure

Time frame

1)To evaluate the effect of Snehpana on body mass index, waist hip ratio and lipid profile. 2)To evaluate the effect of Snehpana and Virechana separately on body mass index, waist hip ratio and lipid profile. 3)To evaluate the effect of Snehpana followed by Virechana and Dashang Guggul as Shamana drug on body mass index, waist hip ratio and lipid profile. Timepoint: 1)On zero day i.e. B.T.value 2)Rukshana Pachana Kvath will be given for 5 days. 3)From 6th day Snehapana will be administered for seven days and assessment will be done on 13th day. 4)Virechana will be given on 16 th day and assessment will be done on 21 rst day. 5) Final assessment will be done on 51 rst day i.e. Dashanga Guggulu will be given for 30 days.

—

Secondary

Measure	Time frame
II} Secondary objectives: 1) To review and study literature of Sthaulya. 2) To review and study literature of Obesity. Timepoint: One and half year	—

Countries

India

Contacts

Public ContactSeema Dhakane

Govt. Ayurved College Nagpur

kabraprakash2711@gmail.com9225226567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026